Physician
Pediatrics Plus, P.C.
Pediatrics Plus, P.C. was paid $14.33M by Medicaid between Jan 2018 and Dec 2024, across 84 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 35% of everything it billed.
33Billing provider infoPEDIATRICS PLUS, P.C.
ANNISTON, AL 36207
ANNISTON, AL 36207
33aNPI1104137439assigned 07/01/2010
33bProvider typePediatrics Physician
28Total paid$14.33M
24GClaims394,292
24DCodes billed84
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Pediatrics Physician providers in Alabama
Rank by total paid#14 of 199
Median peer was paid$702K
This provider vs. median20×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 39,276 | $1.34M | |
| 2019 | 48,016 | $1.51M | |
| 2020 | 38,904 | $1.25M | |
| 2021 | 54,469 | $1.82M | |
| 2022 | 55,285 | $1.91M | |
| 2023 | 81,583 | $3.27M | |
| 2024incomplete | 76,759 | $3.22M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 35% | 60,512 | 56,089 | $5.04M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 12% | 33,868 | 31,286 | $1.78M |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 5.3% | 3,686 | 3,593 | $753K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 5.0% | 4,356 | 4,142 | $721K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 4.7% | 11,846 | 11,617 | $679K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 4.1% | 10,404 | 10,056 | $594K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 3.9% | 26,595 | 25,515 | $562K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | 3.6% | 18,848 | 18,105 | $513K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 3.4% | 8,598 | 8,431 | $489K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 2.3% | 28,070 | 26,902 | $335K |
| 87634 | 2.1% | 6,333 | 5,587 | $298K | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 1.3% | 3,250 | 3,162 | $189K |
72 more codes
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 1.2% | 3,682 | $171K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.1% | 16,411 | $152K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 3,670 | $129K |
| 96127 | <1% | 24,655 | $122K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 4,737 | $117K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 2,582 | $112K |
| 90670 | <1% | 4,830 | $105K | |
| 87581 | <1% | 3,695 | $96K | |
| 87486 | <1% | 3,696 | $96K | |
| 87640 | <1% | 4,504 | $94K | |
| 87498 | <1% | 3,693 | $78K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 909 | $72K |
| 99173 | <1% | 18,245 | $72K | |
| 90461 | <1% | 1,326 | $70K | |
| 92551 | <1% | 15,198 | $66K | |
| 90680 | <1% | 3,210 | $62K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 477 | $62K |
| 81003 | <1% | 21,308 | $60K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 442 | $56K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 6,578 | $54K |
| 90698 | <1% | 2,646 | $51K | |
| 90686 | <1% | 2,491 | $48K | |
| 90671 | <1% | 1,597 | $42K | |
| 90633 | <1% | 2,160 | $42K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,012 | $41K |
| 90697 | <1% | 1,963 | $39K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,720 | $31K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 221 | $28K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 3,427 | $26K |
| D1206 | Topical application of fluoride varnish | <1% | 1,166 | $25K |
| 94010 | <1% | 1,196 | $24K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 837 | $19K |
| 90744 | <1% | 903 | $17K | |
| 92567 | <1% | 1,188 | $13K | |
| 83655 | <1% | 710 | $10K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 168 | $8K |
| 94664 | <1% | 889 | $7K | |
| 90656 | <1% | 335 | $7K | |
| 86308 | <1% | 1,150 | $7K | |
| 90734 | <1% | 83 | $5K | |
| 90651 | <1% | 108 | $5K | |
| 90685 | <1% | 238 | $5K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 153 | $4K |
| 87641 | <1% | 173 | $4K | |
| 87500 | <1% | 173 | $4K | |
| D0145 | Oral evaluation for a patient under three years of age | <1% | 109 | $2K |
| 90688 | <1% | 125 | $2K | |
| 99000 | <1% | 591 | $2K | |
| 85018 | <1% | 754 | $2K | |
| 90710 | <1% | 90 | $2K | |
| 94060 | <1% | 61 | $2K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 140 | $2K |
| 90696 | <1% | 75 | $1K | |
| 69210 | <1% | 65 | $1K | |
| 90619 | <1% | 66 | $1K | |
| 90716 | <1% | 49 | $969.71 | |
| 90707 | <1% | 49 | $969.71 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 602 | $889.01 |
| 88720 | <1% | 148 | $748.98 | |
| 36416 | <1% | 281 | $558.00 | |
| G0444 | Annual depression screening, 5 to 15 minutes | <1% | 46 | $533.24 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 42 | $496.77 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 16 | $402.88 |
| 82947 | <1% | 107 | $394.94 | |
| 90715 | <1% | 12 | $237.48 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 374 | $200.95 |
| 87339 | <1% | 12 | $132.00 | |
| 99050 | <1% | 45 | $41.78 | |
| 96160 | <1% | 41 | $41.66 | |
| G0447 | Face-to-face behavioral counseling for obesity, 15 minutes | <1% | 1,967 | $4.21 |
| 94760 | 0% | 248 | $0.00 | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 0% | 256 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialTHOMAS, CHARLES (OWNER)
| Provider | Location | Paid |
|---|---|---|
| Beyond Boundaries Supportive Living LLC | Little Rock, AR | $9.68M |
| Jay Public Schools | Jay, OK | $458K |
| Hanover Family Physicians P.C. | Mechanicsville, VA | $23K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.